To include your compound in the COVID-19 Resource Center, submit it here.

Roche, Daiichi detail vemurafenib benefit at ASCO

Roche (SIX:ROG; OTCQX:RHHBY) and partner Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) reported data from the Phase III BRIM3 trial

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE